1. Home
  2. VYGR vs RNAC Comparison

VYGR vs RNAC Comparison

Compare VYGR & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.23

Market Cap

203.6M

Sector

Health Care

ML Signal

HOLD

Logo Cartesian Therapeutics Inc.

RNAC

Cartesian Therapeutics Inc.

HOLD

Current Price

$9.18

Market Cap

238.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
RNAC
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.6M
238.9M
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
VYGR
RNAC
Price
$3.23
$9.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$16.50
$34.00
AVG Volume (30 Days)
504.7K
101.0K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
$2,797,000.00
Revenue This Year
$34.04
N/A
Revenue Next Year
$7.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$5.60
52 Week High
$5.55
$11.77

Technical Indicators

Market Signals
Indicator
VYGR
RNAC
Relative Strength Index (RSI) 50.52 65.65
Support Level $2.95 $5.89
Resistance Level $3.30 $10.98
Average True Range (ATR) 0.14 0.44
MACD 0.04 0.14
Stochastic Oscillator 75.95 99.32

Price Performance

Historical Comparison
VYGR
RNAC

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About RNAC Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Share on Social Networks: